182
- Thayu M, Leonard MB, Hyams JS, et al. Improvement in biomarkers of bone formation during
infliximab therapy in pediatric Crohn’s disease: results of the REACH study. Clin Gastroenterol
Hepatol. 2008;6:1378–84. - Griffin LM, Thayu M, Baldassano RN, et al. Improvements in bone density and struc-
ture during anti-TNF-alpha therapy in pediatric Crohn’s disease. J Clin Endocrinol Metab.
2015;100:2630–9. - Pappa HM, Langereis EJ, Grand RJ, Gordon CM. Prevalence and risk factors for hypovita-
minosis D in young patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr.
2011;53:361–4. - Augustine MV, Leonard MB, Thayu M, et al. Changes in vitamin D-related mineral metabo-
lism after induction with anti-tumor necrosis factor-alpha therapy in Crohn’s disease. J Clin
Endocrinol Metab. 2014;99:E991–8. - Long MD, Gulati A, Wohl D, Herfarth H. Immunizations in pediatric and adult patients
with inflammatory bowel disease: a practical case-based approach. Inflamm Bowel Dis.
2015;21:1993–2003. - deBruyn JC, Hilsden R, Fonseca K, et al. Immunogenicity and safety of influenza vaccination
in children with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:25–33. - Mamula P, Markowitz JE, Piccoli DA, Klimov A, Cohen L, Baldassano RN. Immune response
to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol
Hepatol. 2007;5:851–6. - deBruyn J, Fonseca K, Ghosh S, et al. Immunogenicity of influenza vaccine for patients with
inflammatory bowel disease on maintenance infliximab therapy: a randomized trial. Inflamm
Bowel Dis. 2016;22:638–47. - Moses J, Alkhouri N, Shannon A, et al. Hepatitis B immunity and response to booster vaccina-
tion in children with inflammatory bowel disease treated with infliximab. Am J Gastroenterol.
2012;107:133–8. - Fiorino G, Peyrin-Biroulet L, Naccarato P, et al. Effects of immunosuppression on immune
response to pneumococcal vaccine in inflammatory bowel disease: a prospective study.
Inflamm Bowel Dis. 2012;18:1042–7. - Dezfoli S, Horton HA, Thepyasuwan N, et al. combined immunosuppression impairs immuno-
genicity to tetanus and pertussis vaccination among patients with inflammatory bowel disease.
Inflamm Bowel Dis. 2015;21:1754–60. - Lester R, Lu Y, Tung J. Survey of immunization practices in patients with inflammatory bowel
disease among pediatric gastroenterologists. J Pediatr Gastroenterol Nutr. 2015;61:47–51. - Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma asso-
ciated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr
Gastroenterol Nutr. 2007;44:265–7. - Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contrib-
ute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin
Gastroenterol Hepatol. 2011;9:36–41.e1. - Shale M, Kanfer E, Panaccione R, Ghosh S. Hepatosplenic T cell lymphoma in inflammatory
bowel disease. Gut. 2008;57:1639–41. - Dulai PS, Thompson KD, Blunt HB, Dubinsky MC, Siegel CA. Risks of serious infection or
lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a
systematic review. Clin Gastroenterol Hepatol. 2014;12:1443–51; quiz e88-9. - Hyams JS, Dubinsky MC, Baldassano RN, et al. Infliximab is not associated with increased
risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflam-
matory bowel disease. Gastroenterology. 2017;152(8):1901–1914.e3. - Hyams JS, Wilson DC, Thomas A, et al. Natalizumab therapy for moderate to severe Crohn
disease in adolescents. J Pediatr Gastroenterol Nutr. 2007;44:185–91. - Singh N, Deshpande R, Rabizadeh S, Dubinsky M. Real world experience with natalizumab at
a tertiary care pediatric IBD center. J Pediatr Gastroenterol Nutr. 2016;62:863–6.
S. Patel and J. Strople